Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: Experimental studies in pigs

Susan E. Grauer, George Pantely, Jinping Xu, Shuping Ge, George Giraud, Takahiro Shiota, David Sahn

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.

Original languageEnglish (US)
Pages (from-to)938-945
Number of pages8
JournalAmerican Heart Journal
Volume132
Issue number5
DOIs
StatePublished - 1996

Fingerprint

Fluorocarbons
Intravenous Injections
Contrast Media
Swine
perflutren
Coronary Occlusion
Lipids
Echocardiography
Pressure
Partial Pressure
Left Ventricular Function
Pulmonary Artery
Coronary Vessels
Myocardium
Heart Rate
Hemodynamics
Oxygen
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent : Experimental studies in pigs. / Grauer, Susan E.; Pantely, George; Xu, Jinping; Ge, Shuping; Giraud, George; Shiota, Takahiro; Sahn, David.

In: American Heart Journal, Vol. 132, No. 5, 1996, p. 938-945.

Research output: Contribution to journalArticle

Grauer, Susan E. ; Pantely, George ; Xu, Jinping ; Ge, Shuping ; Giraud, George ; Shiota, Takahiro ; Sahn, David. / Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent : Experimental studies in pigs. In: American Heart Journal. 1996 ; Vol. 132, No. 5. pp. 938-945.
@article{b8fad4b3f9834c09a6c20c987ef0dd86,
title = "Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: Experimental studies in pigs",
abstract = "The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.",
author = "Grauer, {Susan E.} and George Pantely and Jinping Xu and Shuping Ge and George Giraud and Takahiro Shiota and David Sahn",
year = "1996",
doi = "10.1016/S0002-8703(96)90002-2",
language = "English (US)",
volume = "132",
pages = "938--945",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent

T2 - Experimental studies in pigs

AU - Grauer, Susan E.

AU - Pantely, George

AU - Xu, Jinping

AU - Ge, Shuping

AU - Giraud, George

AU - Shiota, Takahiro

AU - Sahn, David

PY - 1996

Y1 - 1996

N2 - The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.

AB - The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.

UR - http://www.scopus.com/inward/record.url?scp=0029826145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029826145&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(96)90002-2

DO - 10.1016/S0002-8703(96)90002-2

M3 - Article

C2 - 8892764

AN - SCOPUS:0029826145

VL - 132

SP - 938

EP - 945

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -